Isolation and Properties of Human Vascular Plasminogen Activator

Summary

Improved methods for the isolation of human cadaveric endothelial vascular plasminogen activator have been developed. The enzyme was isolated as the native complex with soluble fibrin by a combination of polyethylene glycol precipitation and hydroxyapatite chromatography. The purified complex was then finally dissociated by affinity chromatography on lysine agarose. The dissociated enzyme was relatively unstable when bioassayed on fibrin plates, however its activity against low molecular weight chromogenic substrates was more stable. The enzymic activity was totally inhibited by DFP, PMSF or DTT and was totally resistant to iodoacetamide or Trasylol, indicating that it was a serine protease but differing in certain respects from urokinase. The specific activity of the native enzyme is ≥ 50,000 CTA units/mg protein, it has a molecular weight of 56,600 and will reform biologically active complexes with soluble fibrin polymers prepared in vitro. Both SFP and various poly-lysine preparations were shown to stimulate the activation of plasminogen by VPA in a spectrophotometric assay based on the rate of plasmin generation assayed against the chromogenic substrate S-2251. Considerable loss of material from purified preparations occurs by adsorption, thus with the limited amount of material available from cadavers, a radioisotopic labelling method was sought using iodination or ³H-DFP labelling, however neither approach was satisfactory. Comparison of VPA activity in cadaveric eluates and in venous occlusion plasma or following infusion of vasopressin analogues showed that all three activities behaved identically in the above purification steps. The affinity of VPA for insoluble fibrin was much higher than that of urokinase, or a human melanoma activator from tissue culture.

Keywords

Fibrinolysis - Endothelial cells - Soluble fibrin polymer

• References

• 1 Pandolfi M, Isacson S, Nilsson IM. Low fibrinolytic activity in the walls of veins in patients with thrombosis. Acta Med Scand 1969; 186: 1-5
• 2 Isacson S, Nilsson IM. Defective fibrinolysis in blood and vein walls in recurrent “idiopathic” venous thrombosis. Acta Chir Scand 1972; 138: 313-319
• 3 Bachmann FW, Fletcher AP, Alkjaersig N, Sherry S. Partial purification and properties of the plasminogen activator from pig heart. Biochemistry 1964; 3: 1578-1585
• 4 Kok P, Astrup T. Isolation and purification of a tissue plasminogen activator and its comparison with urokinase. Biochemistry 1969; 8: 79-86
• 5 Cole ER, Bachmann FW. Purification and properties of a plasminogen activator from pig heart. J Biol Chem 1977; 252: 3729-3737
• 6 Cole E, Bachmann F, Marchant L. Plasminogen activators from porcine tissues: enzymatic and immunological properties. In: Progress in Chemical Fibrinolysis and Thrombolysis. Eds: Davidson JF, Rowan RM, Samama MM, Desnoyers PC. Publ: Raven Press; N.Y.: 1978. 3. 99-106
• 7 Wallén P, Rånby M, Bergsdorf N, Kok P. Purification of porcine and human tissue activator. Thromb Haemostas 1979; 42: 414 (Abstr)
• 8 Rijken DC, Wijngaards G, Zaal de Jong M, Welbergen J. Purification and partial characterization of plasminogen activator from human uterine tissue. Biochim Biophys Acta 1979; 580: 140-153
• 9 Aoki N, von Kaulla KN. The extraction of vascular plasminogen activator from human cadavers and a description of some of its properties. Am J Clin Pathol 1971; 55: 171-179
• 10 Aoki N, von Kaulla KN. Dissimilarity of human vascular plasminogen activator and human urokinase. J Lab Clin Med 1971; 78: 354-362
• 11 Aoki N. Preparation of plasminogen activator from vascular trees of human cadavers. Its comparison with urokinase. J Biochem (Tokyo) 1974; 75: 731-741
• 12 Binder BR, Spragg J, Austen KF. Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates. J Biol Chem 1979; 254: 1998-2003
• 13 Ogston D, Bennett B, Mackie M. Properties of a partially purified preparation of a circulating plasmonogen activator. Thromb Res 1976; 8: 275-284
• 14 Binder BR, Spragg J. Purification of a plasminogen activator from venous occlusion plasma. Thromb; Haemostas: 1979. 42. 362 (Abstr)
• 15 Allen RA, Pepper DS. Vascular plasminogen activator; isolation and properties of the enzyme and its complexes with soluble fibrin. Br J Haematol 1979; 41: 613 (Abstr)
• 16 Pepper DS, Allen RA. Isolation and characterization of human cadaver vascular endothelial activator. In: Progress in Chemical Fibrinolysis and Thrombolysis. Eds: Davidson JF, Rowan RM, Samama MM, Desnoyers PC. Publ: Raven Press; N.Y.: 1978. 3. 91-98
• 17 Weber K, Osborn M. The reliability of molecular weight determinations by dodecyl sulphate-polyacrylamide gel electrophoresis. J Biol Chem 1969; 244: 4406-4412
• 18 Allen Ph. D. RA. Thesis; Edinburgh: 1979
• 19 Thorsen S, Glas-Greenwalt P, Astrup T. Differences in the binding to fibrin of urokinase and tissue plasminogen activator. Thromb Diath Haemorrh 1972; 28: 65-74
• 20 Wallén P, Rånby M. Interaction of activator, inhibitors and plasminogen with each other and with fibrin. Thromb Haemostas 1979; 42: 436 (Abstr)
• 21 Hatton MW C, Regoeczi E. The relevance of the structure of lysine bound to Sepharose for the affinity of rabbit plasminogen. Biochim Biophys Acta 1975; 379: 504-541